The report says that Tecfidera, the oral multiple sclerosis treatment launched several months ago by Biogen will be the main winner.
Credit Suisse sees annual sales of Copaxone falling 90% from about $4 billion in 2012 to less than $400,000 in 2019. The main reasons for this are well known and have long been acknowledged by investors- competition from rival branded drugs that are new on the market such as Tecfidera, for which it sees sales of $5.2 billion annually by 2019, and Novartis's Gilenya, for which it predicts sales of $3.2 billion annually by 2019. Copaxone will also face competition from generic entries after its patent expires.
Credit Suisse does expect Laquinimod, Teva's oral treatment for multiple sclerosis, to come onto the market by 2014, and to start being sold in the US as well in 2017, but sees annual worldwide sales of only $428 million in the US and $649 million in the rest of the world by 2019.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments